^
    1year
    C2i Genomics and OncoDNA begin molecular residual disease testing across Europe (OncoDNA Press Release)
    "OncoDNA...announced the next stage in its partnership with C2i Genomics...The lab uses C2inform, the first CE-IVDD marked software-as-a-medical-device molecular residual disease (MRD) test."
    Licensing / partnership
    |
    C2inform test
    over1year
    C2i Genomics and Ichilov join forces to bring cancer detection and monitoring platform to Israel (Webwire)
    "C2i Genomics...announced its strategic collaboration with the Tel Aviv Sourasky Medical Center (Ichilov)...Together, the organizations will provide precision oncology clinical testing using C2inform, C2i Genomics’ whole genome minimal residual disease (MRD) test to improve cancer detection and monitoring nationwide."
    Licensing / partnership
    |
    C2inform test
    over1year
    Accuracy of genome-wide mutational analysis for tumor-informed ctDNA-guided MRD monitoring in bladder cancer. (ASCO 2023)
    Our results highlight the clinical potential of personalized genome-wide mutation integration as an ultra-sensitive, non-invasive method for MRD detection and treatment response monitoring.
    Circulating tumor DNA
    |
    TP53 (Tumor protein P53) • PIK3CA (Phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha) • FGFR3 (Fibroblast growth factor receptor 3) • RB1 (RB Transcriptional Corepressor 1) • KMT2D (Lysine Methyltransferase 2D) • KDM6A (Lysine Demethylase 6A)
    |
    TP53 mutation • PIK3CA mutation • FGFR3 amplification
    |
    C2inform test
    almost2years
    Detection of circulating tumor DNA by whole genome sequencing enables prediction of recurrence in stage III colorectal cancer patients with great inter-lab reproducibility (AACR 2023)
    C2inform showed great inter-lab reproducibility and enabled prediction of recurrence after treatment and during surveillance. Thus, C2inform has the potential to guide clinical decision-making during the postoperative management of CRC patients.
    Clinical • Circulating tumor DNA
    |
    C2inform test
    almost2years
    C2i Genomics, Riken Genesis expand AI-powered cancer detection technology across Japan (Biospectrumasia)
    "US-headquartered startup C2i Genomics has announced a collaboration with Riken Genesis (RG) Co. to bring minimal residual disease (MRD) cancer monitoring to Japan for pharmaceutical and clinical research...Under this agreement, RG will work with C2i Genomics to commercialise its C2intelligence cloud-based platform and the C2inform MRD test for pharmaceutical and clinical research and eventually for commercial clinical testing in Japan."
    Licensing / partnership
    |
    C2inform test
    almost2years
    AstraZeneca to evaluate C2i Genomics' cancer detection, monitoring platform (Precision Medicine Online)
    "AstraZeneca will evaluate C2i Genomics' whole-genome minimal residual disease assay and cancer-monitoring platform for use in clinical research and drug development efforts, the companies announced Thursday...The agreement is an extension of a previous collaboration in which the companies evaluated C2i Genomics' minimal residual disease (MRD) test across multiple solid cancers using artificially generated samples. The test was able to detect circulating tumor DNA (ctDNA), which was present at varying levels in the samples, down to 0.002 percent allelic frequency, the firms said."
    Clinical
    |
    C2inform test
    over2years
    C2i Genomics launches C2inform MRD test to bring distributed cancer monitoring to cancer centers across Europe (Webwire)
    "C2i Genomics...announced it has launched its C2inform minimal residual disease (MRD) test across Europe after obtaining CE-IVD marking in the EU and UK. The company also announced the completion of several clinical trials across the globe, including leading cancer centers in Europe, U.S. and Singapore."
    Launch Europe
    |
    C2inform test